BioMimetix JV, LLC
11
1
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
36.4%
4 terminated/withdrawn out of 11 trials
42.9%
-43.6% vs industry average
0%
0 trials in Phase 3/4
100%
3 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
Role: collaborator
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
Role: collaborator
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Role: lead
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
Role: lead
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Role: lead
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
Role: lead
Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.
Role: lead
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Role: lead
Evaluation of Topical Application of BMX-010 in Subjects With Rosacea
Role: lead
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
Role: lead
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
Role: lead
All 11 trials loaded